Posaconazole Delayed-Release Tablet by Sinotherapeutics Inc. has been approved by NMPA recently, as First generic for Chinese domestic market (State medical permit No.H20213030).
The company R&D center is focused on formulation research and development activities, it is well managed and equipped with a variety of international brand equipment and instruments. Our team members are highly experienced in providing unique technical solutions to difficult problems encountered during development of water-insoluble drug products, sustained and controlled release drug products, fixed-dose combination drug products and topical drug products.
Sinotherapeutics Inc. is a technology-driven enterprise who is specialized in the research & development, formulation innovation, manufacture, commercialization and distribution of complexed generic products and novel formulation products (505B2). The company commits to the production and supply of pharmaceutical products that meet international quality standards, so as to bring good benefits to patients both at home and abroad, and to make its contributions to the well beings of the pharmaceutical industry, both in China and the rest of the world.
Audits by FDA and NMPA
Find the latest news,company info and insights from our industry lesaders.
The generic drug Posaconazole delayed-release tablets (100mg) Regulatory Approval in Singapore